For those suffering from early signs of Parkinson's, there is now a simple and effective drug delivery system for treatment. Earlier this month, the U.S. Food and Drug Administration (FDA) announced the approval of the combination product Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease. Neupro Patch is the first transdermal patch approved for the treatment of the signs and symptoms of early-stage Parkinson's disease and is manufactured by Schwarz Bioscience of Research Triangle Park, N.C. Schwarz also intends to submit a New Drug Application to the FDA for the treatment of advanced Parkinson’s disease by the end of the year.
Rotigotine is delivered transdermally and is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functions. The symptoms of Parkinson's disease result from
